In the latest trading session, 0.59 million Standard BioTools Inc (NASDAQ:LAB) shares changed hands as the company’s beta touched 1.55. With the company’s most recent per share price at $2.00 changed hands at -$0.06 or -3.16% at last look, the market valuation stands at $742.65M. LAB’s current price is a discount, trading about -52.0% off its 52-week high of $3.04. The share price had its 52-week low at $1.21, which suggests the last value was 39.5% up since then. When we look at Standard BioTools Inc’s average trading volume, we note the 10-day average is 1.56 million shares, with the 3-month average coming to 1.87 million.
Analysts gave the Standard BioTools Inc (LAB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LAB as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Standard BioTools Inc’s EPS for the current quarter is expected to be -0.03.
Standard BioTools Inc (NASDAQ:LAB) trade information
Instantly LAB was in red as seen in intraday trades today. With action 12.71%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 14.00%, with the 5-day performance at 12.71% in the green. However, in the 30-day time frame, Standard BioTools Inc (NASDAQ:LAB) is 2.84% up. Looking at the short shares, we see there were 13.52 million shares sold at short interest cover period of 9.6 days.
The consensus price target for the stock as assigned by Wall Street analysts is 3.25, meaning bulls need an upside of 38.46% from its recent market value. According to analyst projections, LAB’s forecast low is 3.25 with 3.25 as the target high. To hit the forecast high, the stock’s price needs a -62.5% plunge from its current level, while the stock would need to soar -62.5% for it to hit the projected low.
Standard BioTools Inc (LAB) estimates and forecasts
Data shows that the Standard BioTools Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -5.45% over the past 6 months, a 53.66% in annual growth rate that is considerably higher than the industry average of 24.90%. Year-over-year growth is forecast to reach 60.99% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of 43.03M. 2 analysts are of the opinion that Standard BioTools Inc’s revenue for the current quarter will be 45.6M. The company’s revenue for the corresponding quarters a year ago was 28.19M and 45.54M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 52.67%. The estimates for the next quarter sales put growth at 0.13%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 8.72%. The 2025 estimates are for Standard BioTools Inc earnings to increase by 62.06%.
LAB Dividends
Standard BioTools Inc is expected to release its next quarterly earnings report in February.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.86% of Standard BioTools Inc shares while 73.31% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 74.70%. There are 73.31% institutions holding the Standard BioTools Inc stock share, with CASDIN CAPITAL, LLC the top institutional holder. As of 2024-06-30, the company held 17.1782% of the shares, roughly 63.96 million LAB shares worth $113.21 million.
VIKING GLOBAL INVESTORS LP holds the second largest percentage of outstanding shares, with 15.7524% or 58.65 million shares worth $103.81 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 9.27 shares estimated at $18.44 million under it, the former controlled 2.49% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.03% of the shares, roughly 7.57 shares worth around $15.06 million.
